Winthrop Advisory Group LLC Increases Holdings in Merck & Co., Inc. (NYSE:MRK)

Winthrop Advisory Group LLC grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 3.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,052 shares of the company’s stock after buying an additional 226 shares during the period. Winthrop Advisory Group LLC’s holdings in Merck & Co., Inc. were worth $458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. State Street Corp lifted its holdings in Merck & Co., Inc. by 1.2% during the 2nd quarter. State Street Corp now owns 114,073,945 shares of the company’s stock worth $8,943,537,000 after buying an additional 1,385,011 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Merck & Co., Inc. by 3.4% in the 2nd quarter. Geode Capital Management LLC now owns 44,209,748 shares of the company’s stock valued at $3,429,289,000 after purchasing an additional 1,435,230 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Merck & Co., Inc. by 9.4% in the 2nd quarter. Franklin Resources Inc. now owns 38,804,709 shares of the company’s stock valued at $3,017,843,000 after purchasing an additional 3,348,929 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Merck & Co., Inc. by 15.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,293,818 shares of the company’s stock valued at $2,044,871,000 after purchasing an additional 3,594,415 shares during the last quarter. Finally, Morgan Stanley lifted its holdings in shares of Merck & Co., Inc. by 17.1% in the 2nd quarter. Morgan Stanley now owns 26,289,496 shares of the company’s stock valued at $2,044,534,000 after purchasing an additional 3,832,086 shares during the last quarter. 71.79% of the stock is owned by institutional investors.

In related news, insider Sanat Chattopadhyay sold 24,619 shares of the company’s stock in a transaction that occurred on Friday, October 29th. The stock was sold at an average price of $87.32, for a total value of $2,149,731.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Caroline Litchfield sold 18,335 shares of the company’s stock in a transaction that occurred on Thursday, November 4th. The shares were sold at an average price of $91.00, for a total value of $1,668,485.00. The disclosure for this sale can be found here. Insiders have sold a total of 936,784 shares of company stock worth $78,682,559 in the last quarter. 0.32% of the stock is currently owned by insiders.

NYSE MRK traded down $0.52 on Thursday, hitting $82.28. 8,534,741 shares of the company’s stock were exchanged, compared to its average volume of 12,415,974. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.31 and a quick ratio of 1.07. The firm’s 50-day moving average price is $80.47 and its two-hundred day moving average price is $78.04. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $91.40. The firm has a market cap of $207.83 billion, a price-to-earnings ratio of 29.07, a P/E/G ratio of 2.11 and a beta of 0.46.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Wednesday, October 27th. The company reported $1.75 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.55 by $0.20. Merck & Co., Inc. had a return on equity of 48.21% and a net margin of 14.64%. The company had revenue of $13.15 billion for the quarter, compared to analysts’ expectations of $12.32 billion. During the same quarter in the previous year, the firm posted $1.74 EPS. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. On average, research analysts predict that Merck & Co., Inc. will post 5.76 earnings per share for the current fiscal year.

MRK has been the subject of several research reports. Berenberg Bank reissued a “hold” rating and issued a $92.00 target price (up from $86.00) on shares of Merck & Co., Inc. in a report on Sunday, October 10th. Morgan Stanley boosted their target price on Merck & Co., Inc. from $88.00 to $90.00 and gave the company an “equal weight” rating in a report on Friday, October 29th. BMO Capital Markets initiated coverage on Merck & Co., Inc. in a report on Thursday, November 18th. They issued a “market perform” rating and a $91.00 target price for the company. Mizuho assumed coverage on Merck & Co., Inc. in a report on Thursday, October 28th. They issued a “buy” rating and a $99.00 target price for the company. Finally, Barclays boosted their price target on Merck & Co., Inc. from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Monday, November 1st. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $95.73.

Merck & Co., Inc. Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Read More: What is the CAC 40 Index?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.